Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (2)

Trial Status

Recruiting4
Not Yet Recruiting2
Enrolling By Invitation1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07569081Phase 2Not Yet RecruitingPrimary

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT06782373Phase 2Recruiting

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT05969821Not Yet Recruiting

Clonal Hematopoiesis of Immunological Significance

NCT07102849Enrolling By Invitation

Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study

NCT06377462RecruitingPrimary

Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

NCT06538181Phase 1Recruiting

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT05200715Recruiting

AutoInflammatory Disease Alliance Registry (AIDA)

Showing all 7 trials

Research Network

Activity Timeline